McKesson (MCK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, McKesson (MCK) reported revenue of $105.38 billion, up 7.7% over the same period last year. EPS came in at $9.93, compared to $8.26 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $104.39 billion, representing a surprise of +0.95%. The company delivered an EPS surprise of +5.19%, with the consensus EPS estimate being $9.44.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

• Revenue- North American Pharmaceutical: $86.77 billion versus the two-analyst average estimate of $86.53 billion. The reported number represents a year-over-year change of -3.5%.
• Revenue- Prescription Technology Solutions: $1.57 billion versus $1.5 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
• Revenue- Oncology & Multispecialty: $14.22 billion versus the two-analyst average estimate of $12.71 billion.
• Revenue- Medical-Surgical Solutions: $2.82 billion versus $2.79 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.
• Adjusted Operating Profit- North American Pharmaceutical: $894 million compared to the $806.45 million average estimate based on two analysts.
• Adjusted Operating Profit- Medical-Surgical Solutions: $195 million versus $241.06 million estimated by two analysts on average.
• Adjusted Operating Profit- Corporate: $-144 million compared to the $-142.83 million average estimate based on two analysts.
• Adjusted Operating Profit- Oncology & Multispecialty: $405 million versus $367.82 million estimated by two analysts on average.
• Adjusted Operating Profit- Prescription Technology Solutions: $303 million compared to the $302.62 million average estimate based on two analysts.

View all Key Company Metrics for McKesson here>>>

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research